Home
report store
congenital hyperinsulinism market analysis

Congenital Hyperinsulinism - Market Insight, Epidemiology and Market Forecast - 2028

Published Date : 2019

Pages : 152

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
- Sample Request

congenital hyperinsulinism market analysis

DelveInsight's 'Congenital Hyperinsulinism (CHI) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Congenital Hyperinsulinism in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Congenital Hyperinsulinism from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017-2028

Congenital Hyperinsulinism - Disease Understanding and Treatment Algorithm

Congenital Hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma. Congenital Hyperinsulinism affects approximately 1 in 50,000 newborns. This condition is more common in certain populations, affecting up to 1 in 2,500 newborns. Congenital Hyperinsulinism, refers to a clinically, genetically and morphologically heterogeneous group of disorders associated with dysregulated Insulin secretion.

The DelveInsight Congenital Hyperinsulinism market report gives the thorough understanding of the Congenital Hyperinsulinism by including details such as disease Introduction, Pancreatic ??Cell Physiology, Glucose Metabolism and Insulin Secretion, Types of Congenital Hyperinsulinism, causes, Molecular basis, clinical presentation and symptoms, Pathophysiology, Genetics of Congenital Hyperinsulinism, Diagnosis, and Differential diagnosis. It also provides treatment algorithms and treatment guidelines for Congenital Hyperinsulinism in the US, Europe, and Japan.

Congenital Hyperinsulinism Epidemiology

The Congenital Hyperinsulinism epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Population of Congenital Hyperinsulinism, Total Diagnosed Prevalent Population of Congenital Hyperinsulinism, Type specific Diagnosed Prevalence of Congenital Hyperinsulinism, Sub-type specific Diagnosed Prevalence of Congenital Hyperinsulinism) scenario of Congenital Hyperinsulinism in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

A study titled as “Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders” by Charles A. Stanley concluded that Hypoglycemia is present at birth, but recognition is often delayed because symptoms of hypoglycemia in neonates can be subtle, and low concentrations of plasma glucose are often confused with the commonly observed transitional HI of normal neonates. This transitional neonatal HI may reflect persistence of a lower glucose threshold for Insulin release that is necessary to maintain fetal growth. Furthermore, The HI associated with HNF4A and HNF1a mutations may be transient in early infancy or may persist into later childhood and is usually responsive to diazoxide. According to DelveInsight, the total number of prevalent population of Congenital Hyperinsulinism will change from the study period 2017-2028.

Congenital Hyperinsulinism Drug Chapters

This segment of the Congenital Hyperinsulinism report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment of Congenital Hyperinsulinism, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the Incident population of Congenital Hyperinsulinism and awareness of the disease. The overall dynamics of Congenital Hyperinsulinism market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Zealand Pharma, Rezolute, Xeris Pharmaceuticals and some others, will significantly increase the market during the forecast period (2019-2028).

Congenital Hyperinsulinism Market Outlook

The Congenital Hyperinsulinism market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Congenital Hyperinsulinism in 7MM is expected to change from 2019-2028.

Congenital Hyperinsulinism Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Congenital Hyperinsulinism such as Dasiglucagon (Zealand Pharma), RZ358 (Rezolute), CSI-Glucagon (Continuous Subcutaneous Glucagon Infusion) (Xeris Pharmaceuticals) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Congenital Hyperinsulinism market.

Congenital Hyperinsulinism Report Insights

• Patient Population

• Therapeutic Approaches

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Congenital Hyperinsulinism Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Congenital Hyperinsulinism Report Assessment

• Current Treatment Practices

• Unmet Needs

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Congenital Hyperinsulinism market

• Organize sales and marketing efforts by identifying the best opportunities for Congenital Hyperinsulinism market

• To understand the future market competition in the Congenital Hyperinsulinism market.

1. Key Insights

2. Congenital Hyperinsulinism Market Overview At A Glance

2.1.1. Market Share (%) Distribution Of Congenital Hyperinsulinism In 2017

2.1.2. Market Share (%) Distribution Of Congenital Hyperinsulinism In 2028

3. Disease Background And Overview: Congenital Hyperinsulinism (CHI)

3.1. Introduction

3.2. Pancreatic ? Cell Physiology, Glucose Metabolism AndInsulinSecretion

3.3. Types Of Congenital Hyperinsulinism

3.3.1. Histological Subtypes of Congenital

3.4. Causes Of CHI

3.4.1. Transient Hyperinsulinism

3.4.2. Persistent HI

3.5. Molecular Basis

3.5.1. Modes of Inheritance

3.6. Clinical Presentation and Symptoms

3.6.1. During the neonatal period

3.6.2. During infancy and childhood

3.6.3. Syndromic CHI are usually diazoxide-responsive

3.7. Pathophysiology

3.8. Genetics Of Congenital Hyperinsulinism

3.8.1. Pancreatic ?-cell KATP Channel Defects

3.8.2. Glutamate Dehydrogenase (GDH) and Hyperinsulinaemia-hyperammonaemia Syndrome (HI/HA)

3.8.3. Mutations in Mitochondrial L-3-Hydroxyacyl-CoA Dehydrogenase (HADH) and CHI

3.8.4. Activating Mutations in GCK and CHI

3.8.5. Mutations in Solute Carrier Family 16 Member 1 (SLC16A1) and Exercise-induced CHI

3.8.6. Hepatocyte Nuclear Factor (HNF) 1A?&4? (HNF1?&4?) and CHI

3.8.7. Mutations in the Mitochondrial Uncoupling Protein 2 (UCP2) and CHI

3.8.8. Somatic overexpression of Hexokinase 1 (HK1) and CHI

3.8.9. Phosphoglucomutase 1 (PGM1) Gene Mutations and CHI

3.8.10. Phosphomannomutase 2 (PMM2) Gene Mutations and CHI

3.9. Diagnosis

3.10. Differential Diagnosis

4. Epidemiology And Patient Population

4.1. Key Findings

4.2. 7MM Total Patient Population of Congenital Hyperinsulinism

4.3. 7MM Total Diagnosed Patient Population of Congenital Hyperinsulinism

5. Country Wise-Epidemiology Of Congenital Hyperinsulinism

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Congenital Hyperinsulinism Prevalent Population in the United States

5.1.3. Congenital Hyperinsulinism Diagnosed Prevalent Population in the United States

5.1.4. Congenital Hyperinsulinism Type-specific Diagnosed Prevalence in the United States

5.1.5. Congenital Hyperinsulinism Sub-type specific Diagnosed Prevalence in the United States

6. EU5 COUNTRIES

6.1. Assumptions and Rationale

6.2. Germany

6.2.1. Congenital Hyperinsulinism Prevalent Population in Germany

6.2.2. Congenital Hyperinsulinism Diagnosed Prevalent Population in Germany

6.2.3. Congenital Hyperinsulinism Type-specific Diagnosed Prevalence in Germany

6.2.4. Congenital Hyperinsulinism Sub-type specific Diagnosed Prevalence in Germany

6.3. France

6.3.1. Congenital Hyperinsulinism Prevalent Population in France

6.3.2. Congenital Hyperinsulinism Diagnosed Prevalent Population in France

6.3.3. Congenital Hyperinsulinism Type-specific Diagnosed Prevalence in France

6.3.4. Congenital Hyperinsulinism Sub-type specific Diagnosed Prevalence in France

6.4. Italy

6.4.1. Congenital Hyperinsulinism Prevalent Population in Italy

6.4.2. Congenital Hyperinsulinism Diagnosed Prevalent Population in Italy

6.4.3. Congenital Hyperinsulinism Type-specific Diagnosed Prevalence in Italy

6.4.4. Congenital Hyperinsulinism Sub-type specific Diagnosed Prevalence in Italy

6.5. Spain

6.5.1. Congenital Hyperinsulinism Prevalent Population in Spain

6.5.2. Congenital Hyperinsulinism Diagnosed Prevalent Population in Spain

6.5.3. Congenital Hyperinsulinism Type-specific Diagnosed Prevalence in Spain

6.5.4. Congenital Hyperinsulinism Sub-type specific Diagnosed Prevalence in Spain

6.6. United Kingdom

6.6.1. Congenital Hyperinsulinism Prevalent Population in the United Kingdom

6.6.2. Congenital Hyperinsulinism Diagnosed Prevalent Population in the United Kingdom

6.6.3. Congenital Hyperinsulinism Type-specific Diagnosed Prevalence in the United Kingdom

6.6.4. Congenital Hyperinsulinism Sub-type specific Diagnosed Prevalence in the United Kingdom

6.7. Japan

6.7.1. Congenital Hyperinsulinism Prevalent Population in Japan

6.7.2. Congenital Hyperinsulinism Diagnosed Prevalent Population in Japan

6.7.3. Congenital Hyperinsulinism Type-specific Diagnosed Prevalence in Japan

6.7.4. Congenital Hyperinsulinism Sub-type specific Diagnosed Prevalence in Japan

7. Treatment

7.1. Emergency/Prompt Management

7.2. Standard Therapies (Long Term Management)

7.2.1. Surgery

7.2.2. Diazoxide

7.2.3. Octreotide

7.2.4. Calcium Channel Antagonists

7.2.5. Glucagon

7.3. Potential Novel Therapies

8. The United States Guidelines On Congenital Hyperinsulinism

8.1. Management Of Neonates, Infants, And Children With A Persistent Hypoglycemia Disorder

8.1.1. Neonates, Infants, and Children with Hypoglycemia Disorders

9. European Guidelines On Congenital Hyperinsulinism

9.1. Management Of Hypoglycemia

9.1.1. Hypoglycemia Pathway 1

9.1.2. Pathway 2 for Hypoglycemia

10. Japanese Guidelines On Congenital Hyperinsulinism

10.1. First Line Treatment

10.2. Second Line Treatment

10.3. Surgical Treatment

10.4. End Of Treatment

11. Treatment Algorithm

12. Unmet Needs

13. Marketed Drugs

13.1. Proglycem: Teva Pharmaceuticals

13.1.1. Drug Description

13.1.2. Other Development Activities

13.1.3. Product Profile

14. Emerging Drugs

14.1. Key Cross Competition

14.2. Dasiglucagon: Zealand Pharma

14.2.1. Product Description

14.2.2. Other Development Activities

14.2.3. Clinical Development

14.2.4. Product Profile

14.3. RZ358: Rezolute

14.3.1. Product Description

14.3.2. Other Development Activities

14.3.3. Clinical Development

14.3.4. Product Profile

14.4. CSI-Glucagon (Continuous Subcutaneous Glucagon Infusion): Xeris Pharmaceuticals

14.4.1. Product Description

14.4.2. Other Development Activities

14.4.3. Clinical Development

14.4.4. Product Profile

15. Congenital Hyperinsulinism: 7 Major Market Analysis

15.1. Key Findings

15.2. Market Size Of Congenital Hyperinsulinism in the 7MM

16. The United States Market Outlook

16.1. United States Market Size

16.1.1. Total Market Size Of Congenital Hyperinsulinism

16.1.2. Market Size By Therapies

17. Eu-5 Countries: Market Outlook

17.1. Germany

17.1.1. Total Market Size Of Congenital Hyperinsulinism

17.1.2. Market Size By Therapies

17.2. France

17.2.1. Total Market Size Of Congenital Hyperinsulinism

17.2.2. Market Size By Therapies

17.3. Italy

17.3.1. Total Market Size Of Congenital Hyperinsulinism

17.3.2. Market Size By Therapies

17.4. Spain

17.4.1. Total Market Size Of Congenital Hyperinsulinism

17.4.2. Market Size By Therapies

17.5. United Kingdom

17.5.1. Total Market Size Of Congenital Hyperinsulinism

17.5.2. Market Size By Therapies

18. Japan: Market Outlook

18.1. Japan Market Size

18.1.1. Total Market Size Of Congenital Hyperinsulinism

18.1.2. Market Size By Therapies

19. Market Drivers

20. Market Barriers

21. Appendix

21.1. Report Methodology

22. Delveinsight Capabilities

23. Disclaimer

24. About Delveinsight

List of Tables:

Table 1: Total Population of Congenital Hyperinsulinism in the 7MM (2017-2028)

Table 2: Total Diagnosed Population of Congenital Hyperinsulinism in the 7MM (2017-2028)

Table 3: Congenital Hyperinsulinism Prevalent Population in the United States (2017-2028)

Table 4: Congenital Hyperinsulinism Diagnosed Prevalent Population in the United States (2017-2028)

Table 5: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in the United States (2017-2028)

Table 6: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in the United States (2017-2028)

Table 7: Congenital Hyperinsulinism Prevalent Population in Germany (2017-2028)

Table 8: Congenital Hyperinsulinism Diagnosed Prevalent Population in Germany (2017-2028)

Table 9: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in Germany (2017-2028)

Table 10: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in Germany (2017-2028)

Table 11: Congenital Hyperinsulinism Prevalent Population in France (2017-2028)

Table 12: Congenital Hyperinsulinism Diagnosed Prevalent Population in France (2017-2028)

Table 13: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in France (2017-2028)

Table 14: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence In France (2017-2028)

Table 15: Congenital Hyperinsulinism Prevalent Population in Italy (2017-2028)

Table 16: Congenital Hyperinsulinism Diagnosed Prevalent Population in Italy (2017-2028)

Table 17: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in Italy (2017-2028)

Table 18: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence In Italy (2017-2028)

Table 19: Congenital Hyperinsulinism Prevalent Population in Spain (2017-2028)

Table 20: Congenital Hyperinsulinism Diagnosed Prevalent Population in Spain (2017-2028)

Table 21: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in Spain (2017-2028)

Table 22: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in Spain (2017-2028)

Table 23: Congenital Hyperinsulinism Prevalent Population in the United Kingdom (2017-2028)

Table 24; Congenital Hyperinsulinism Diagnosed Prevalent Population in the United Kingdom (2017-2028)

Table 25: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in the United Kingdom (2017-2028)

Table 26: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in the United Kingdom (2017-2028)

Table 27: Congenital Hyperinsulinism Prevalent Population in Japan (2017-2028)

Table 28: Congenital Hyperinsulinism Diagnosed Prevalent Population in Japan (2017-2028)

Table 29: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in Japan (2017-2028)

Table 30: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in Japan (2017-2028)

Table 31: Comparison of Emerging Drugs Under Development

Table 32: Clinical Trial Description

Table 33: Clinical Trial Description

Table 34: Clinical Trial Description

Table 35: 7 Major Market Size of Congenital Hyperinsulinism In USD Million (2017-2028)

Table 36: United States Market Size of Congenital Hyperinsulinism , USD Million (2017-2028)

Table 37: Market Size Of Congenital Hyperinsulinism By Therapies In The United States, In USD Million (2017-2028)

Table 38: Market Size of Congenital Hyperinsulinism In Germany, in USD Million (2017-2028)

Table 39: Market Size of Congenital Hyperinsulinism By Therapies In Germany, n USD Million (2017-2028)

Table 40: Market Size of Congenital Hyperinsulinism In France, In USD Million (2017-2028)

Table 41: Market Size of Congenital Hyperinsulinism By Therapies In France, in USD Million (2017-2028)

Table 42: Market Size of Congenital Hyperinsulinism In Italy, in USD Million (2017-2028)

Table 43: Market Size of Congenital Hyperinsulinism By Therapies in Italy, In USD Million (2017-2028)

Table 44: Market Size of Congenital Hyperinsulinism In Spain, in USD Million (2017-2028)

Table 45: Market Size of Congenital Hyperinsulinism By Therapies in Spain, In USD Million (2017-2028)

Table 46: Market Size of Congenital Hyperinsulinism in the United Kingdom, in USD Million (2017-2028)

Table 47: Market Size of Congenital Hyperinsulinism By Therapies in the United Kingdom, In USD Million (2017-2028)

Table 48: Market Size of Congenital Hyperinsulinism In Japan, in USD Million (2017-2028)

Table 49: Market Size of Congenital Hyperinsulinism By Therapies in Japan, In USD Million (2017-2028)

List of Figures:

Figure 1: Regulation of Insulin Release From Pancreatic ?-Cell

Figure 2: Histological Subtypes of CHI (Focal And Diffuse)

Figure 3: Persistent CHI

Figure 4: Mutations Occurred throughout SUR1 And KIR6

Figure 5: Glucose Induced Insulin Secretion Pathway

Figure 6: KATP Channel-Dependent Pathways Of Insulin Secretion

Figure 7: Diagnostic Tree For CHI

Figure 8: Total Patient Population of Congenital Hyperinsulinism in the 7MM

Figure 9: Total Diagnosed Patient Population of Congenital Hyperinsulinism in the 7MM

Figure 10: Congenital Hyperinsulinism Prevalent Population in the United States (2017-2028)

Figure 11: Congenital Hyperinsulinism Diagnosed Prevalent Population in the United States (2017-2028)

Figure 12: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in the United States (2017-2028)

Figure 13: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in the United States (2017-2028)

Figure 14: Congenital Hyperinsulinism Prevalent Population in Germany (2017-2028)

Figure 15: Congenital Hyperinsulinism Diagnosed Prevalent Population in Germany (2017-2028)

Figure 16: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in Germany (2017-2028)

Figure 17: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in Germany (2017-2028)

Figure 18: Congenital Hyperinsulinism Prevalent Population in France (2017-2028)

Figure 19: Congenital Hyperinsulinism Diagnosed Prevalent Population in France (2017-2028)

Figure 20: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in France (2017-2028)

Figure 21: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in France (2017-2028)

Figure 22: Congenital Hyperinsulinism Prevalent Population in Italy (2017-2028)

Figure 23: Congenital Hyperinsulinism Diagnosed Prevalent Population in Italy (2017-2028)

Figure 24: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in Italy (2017-2028)

Figure 25: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence In Italy (2017-2028)

Figure 26: Congenital Hyperinsulinism Prevalent Population in Spain (2017-2028)

Figure 27: Congenital Hyperinsulinism Diagnosed Prevalent Population in Spain (2017-2028)

Figure 28: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in Spain (2017-2028)

Figure 29: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in Spain (2017-2028)

Figure 30: Congenital Hyperinsulinism Prevalent Population in the United Kingdom (2017-2028)

Figure 31: Congenital Hyperinsulinism Diagnosed Prevalent Population in the United Kingdom (2017-2028)

Figure 32: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in the United Kingdom (2017-2028)

Figure 33: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in the United Kingdom (2017-2028)

Figure 34: Congenital Hyperinsulinism Prevalent Population in Japan (2017-2028)

Figure 35: Congenital Hyperinsulinism Diagnosed Prevalent Population in Japan (2017-2028)

Figure 36: Congenital Hyperinsulinism Type-Specific Diagnosed Prevalence in Japan (2017-2028)

Figure 37: Congenital Hyperinsulinism Sub-Type Specific Diagnosed Prevalence in Japan (2017-2028)

Figure 38: Algorithm For the Treatment of Hyperinsulinism

Figure 39: Unmet Needs of Congenital Hyperinsulinism

Figure 40: 7 Major Market Size of Congenital Hyperinsulinism in USD Million (2017-2028)

Figure 41: Market Size Of Congenital Hyperinsulinism in the United States, USD Millions (2017-2028)

Figure 42: Market Size of Congenital Hyperinsulinism by Therapies In The Us, In USD Million (2017-2028)

Figure 43: Market Size of Congenital Hyperinsulinism in Germany, USD Million (2017-2028)

Figure 44: Market Size Of Congenital Hyperinsulinism By Therapies, In Germany, In USD Million (2017-2028)

Figure 45: Market Size Of Congenital Hyperinsulinism In France, USD Million (2017-2028)

Figure 46: Market Size Of Congenital Hyperinsulinism By Therapies, In France, In USD Million (2017-2028)

Figure 47: Market Size Of Congenital Hyperinsulinism In Italy, USD Million (2017-2028)

Figure 48: Market Size Of Congenital Hyperinsulinism By Therapies In Italy, In USD Million (2017-2028)

Figure 49: Market Size Of Congenital Hyperinsulinism In Spain, USD Million (2017-2028)

Figure 50: Market Size Of Congenital Hyperinsulinism By Therapies In Spain, In USD Million (2017-2028)

Figure 51: Market Size Of Congenital Hyperinsulinism In The UK, USD Million (2017-2028)

Figure 52: Market Size Of Congenital Hyperinsulinism By Therapies In The United Kingdom, In USD Million

Figure 53: Market Size Of Congenital Hyperinsulinism In Japan, USD Million (2017-2028)

Figure 54: Market Size Of Congenital Hyperinsulinism By Therapies In Japan, In USD Million (2017-2028)

Figure 55: Market Drivers

Figure 56: Market Barriers

Related Reports

Offer